Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787935 | 0.82 | CYP1A2 (0.57) | CYP1A2CYP2C19GAACYP2D6POLB | |
| SCHEMBL2092283 | 0.78 | POLB (0.55) | CYP1A2CYP2C19GAACYP2D6POLB | |
| SCHEMBL14449300 | 0.78 | POLB (0.59) | CYP1A2CYP2C19GAACYP2D6POLB | |
| SCHEMBL3358178 | 0.78 | ST14 (0.43) | RAB9ACYP3A4LMNAALDH1A1KMT2A | |
| SCHEMBL5209430 | 0.76 | MAPT (0.44) | CYP1A2CYP2C19CYP2D6RAB9ACYP3A4 | |
| SCHEMBL125543 | 0.76 | ALDH1A3 (0.64) | CYP1A2CYP2C19GAACYP2D6POLB | |
| SCHEMBL8163509 | 0.76 | CYP1A2 (0.64) | CYP1A2CYP2C19GAACYP2D6POLB | |
| SCHEMBL805120 | 0.76 | POLB (0.57) | CYP1A2CYP2C19GAACYP2D6POLB | |
| SCHEMBL1145768 | 0.76 | IDO1 (0.57) | CYP3A4ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL13735220 | 0.75 | ALDH1A3 (0.59) | CYP1A2CYP2C19GAACYP2D6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SUZHOU M-CONJ BIOTECH CO., LTD. (CN) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | TLR9, TLR8, TLR7 | CYP1A2 4130/4885CYP2C19 4531/4885GAA 1766/4885 |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | CYP1A2 4767/4885CYP2C19 4855/4885GAA 779/4885 |
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | CYP1A2 3585/4885CYP2C19 3093/4885GAA 2416/4885 |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | CYP1A2 3585/4885CYP2C19 3093/4885GAA 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.